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Antipsychotic medications act as either antagonists or partial agonists of the 
dopamine D2 receptor (DRD2) and antipsychotic drugs vary widely in their binding 
affinity for the D2 receptor (Kapur and Seeman 2000).  The DRD2 957C>T (rs6277) 
polymorphism has previously been associated with schizophrenia (Lawford et al. 
2005) and the T-allele of the 957C>T polymorphism is associated with reduced 
mRNA stability and synthesis of the dopamine D2 receptor (Duan et al. 2003).  The 
aim of the study was to determine if the rs6277 polymorphism predicts some of the 
variability of positive and negative symptoms observed in schizophrenia patients 
being treated with antipsychotic medication.   
Positive and negative symptom scale (PANSS) ratings and DRD2 957C>T genotypes 
were determined in 142 schizophrenia patients who were treated with antipsychotic 
drugs (clozapine, olanzapine, typicals and risperidone).  DSM (Diagnostic and 
Statistical Manual of Mental Disorders) IV diagnosis of schizophrenia was confirmed 
by at least two independent psychiatrists.  Patients had never been diagnosed with 
other psychiatric disorders, including schizoaffective disorder, major depressive 
episode with psychotic features, or bipolar disorder.  No patients were treated with 
antidepressants, anxiolytic agents, or mood-stabilizing psychotropic medications and 
all were maintained on a constant dose of antipsychotic medication for a minimum of 
three weeks.  The mean age of patients was 36.2 years (s.d. + 12.1 years) and the 
mean age of patients first diagnosed with schizophrenia was 23.4 years (s.d. + 7.47 
years).  Patients had been diagnosed with schizophrenia for an average of 13 years 
and despite treatment with antipsychotic medication they continued to experience 
positive and negative symptoms.  PANSS scales analysed included PANSS rating 
scale-positive scale-Likert scoring system, PANSS rating scale-negative scale-Likert 
scoring system, PANSS rating scale-general scale G14: poor impulse control, PANSS 
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rating scale-positive scale-total score/49, PANSS rating scale-negative scale -total 
score/49, PANSS rating scale-general scale G11: poor attention), PANSS rating scale-
general scale G12: lack of judgement and insight and PANSS rating scale (modified 
version)-total score/119.  All statistical tests including analysis of variance (ANOVA), 
post-hoc pair-wise comparisons and t-tests were performed by SPSS version 16.   
Firstly, PANSS rating scores were correlated with antipsychotic drug treatment.  
Analysis of variance revealed significant differences in PANSS G12 general score 
(lack of judgement and insight) among the four medication groups (P=0.018, 
F=3.484).  PANSS G12 scores the impaired awareness or understanding of one’s own 
psychiatric condition and life situation as well as measuring compliance of treatment.  
This is an important measure as a large percentage of schizophrenic patients are 
noncompliant in treatment and between 50% and 80% of patients with schizophrenia 
do not believe they have a mental disorder (Amador and Gorman 1998).  Response to 
treatment and side effects may affect compliance in patients with schizophrenia 
(Hofer et al. 2002).  Patients treated with typicals had poorer G12 scores compared to 
patients treated with clozapine (Tukey P=0.016, Bonferroni P=0.018) or olanzapine 
(Tukey P=0.048, Bonferroni P=0.060).  Analysis of variance revealed no significant 
differences in other PANSS rating measurements between drug groups.  No 
significant differences between drug groups were observed for gender, age, BMI, 
onset age, family history, number of admissions and drug use.   
In the second part of the study PANSS ratings were correlated with genotype in 
patients receiving one of four types of antipsychotic medications.  Significant 
associations were found between alleles and PANSS poor attention ratings (P=0.019, 
T=-2.441) and PANSS negative ratings (P=0.031, T=-2.203) (Table 1).  No 
significant associations were found between alleles and PANSS Positive, PANSS 
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poor impulse control, PANSS Positive Total, PANSS Negative Total and PANSS 
Total rating scores.  Association with PANSS poor attention was also significant at 
the genotype level (P=0.042).  Post-hoc pair-wise comparisons including Tukey and 
Bonferroni were undertaken to test differences between groups revealing significant 
PANSS (poor attention) mean score differences between individuals with the CC and 
TT genotypes (Tukey P=0.038, Bonferroni P=0.045) but not between CC vs CT or 
CT vs TT groups.  The association seen between PANSS negative rating and alleles 
did not hold up at the genotype level (P=0.156) and was not significant after Tukey 
and Bonferroni multiple comparisons.   
Our study indicates that the 957C>T polymorphism in the DRD2 gene may explain 
some of the variability of symptom severity seen in patients receiving antipsychotics.  
Our positive association is promising for future schizophrenia treatment options but 
must be seen as exploratory until replication in another sample set is performed.  If 
the genetic component of schizophrenia susceptibility can be identified then more 
effective and targeted treatments could be developed.  
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Table 1.  PANSS G11 poor attention and PANSS negative symptom scores in 
patients with the C or T DRD2 allele receiving antipsychotic medication for 
schizophrenia 
Drug group Mean PANSS G11 (s.d.) Mean Negative symptoms (s.d.)
 C-allele T-allele P C-allele  T-allele P 
 
All groups 
n=142 
 
 
2.16 (0.95) 
n=160 
 
2.32 (1.28) 
n=124 
 
0.245 
 
2.99 (1.06) 
n=160 
 
3.15 (1.23) 
n=124 
 
0.250
Clozapine 
n=31 
 
2.25 (0.91) 
n=36 
3.04 (1.46) 
n=26 
0.019 2.94 (1.19) 
n=36 
3.62 (1.17) 
n=26 
0.031
Olanzapine 
n=37 
 
2.05 (1.01) 
n=40 
2.35 (1.50) 
n=34 
0.320 2.85 (1.27) 
n=40 
3.35 (1.54) 
n=34 
0.128
Typicals  
n=28 
 
2.21 (0.99) 
n=28 
2.00 (0.94) 
n=28 
0.420 3.32 (0.67) 
n=28 
3.12 (0.91) 
n=26 
0.345
Risperidone 
n=46 
2.09 (0.87) 
n=54 
2.03 (0.94) 
n=38 
0.730 2.93 (0.93) 
n=54 
2.68 (1.02) 
n=38 
0.240
 
